[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$foMEb7TjzJY4wk8VjlA01eehWZyTw9TUHaMhr9A3BWos":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":34,"phaseBuckets":73,"rows":80},"Pontificia Universidad Catolica de Chile",[4],208,false,36,9,123933,130,[13,16,19,21,24,26,28,31],{"name":14,"count":15},"Anesthesia",13,{"name":17,"count":18},"Pain",7,{"name":20,"count":18},"Covid19",{"name":22,"count":23},"Breast Cancer",6,{"name":25,"count":23},"Septic Shock",{"name":27,"count":23},"Obesity",{"name":29,"count":30},"Critical Illness",5,{"name":32,"count":33},"Surgery",4,[35,40,45,50,55,60,64,69],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT06758024","PROactive and Early Infliximab Monitoring and OPTimization in Inflammatory Bowel Disease","2026-01","Infliximab",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05472337","Effect of Colchicine on Coronary Reperfusion in Patients With Acute Coronary Syndrome","2026-03-30","Colchicine",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06667869","multipaRameter mOnitoring systeM for sedAtion iNThe ICu","2026-07-01","Sedative",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT07253012","AI-Assisted Analgesia Copilot System","2026-10-27","Hemodynamic monitor, BIS, TOF, ANI, anesthesia machine and infusion pumps",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT07324499","Effect of Dexamethasone on Plasma Levels of Bupivacaine and Dexamethasone After a Single-injection Interscalene Nerve Block.","2026-12-01","administration of dexamethasone intravenously",{"nctId":61,"briefTitle":62,"date":58,"intervention":63},"NCT07396129","Assessing the Efficacy of a High-Dose Lidocaine-Tetracaine Cream for the Treatment of Peripheral Neuropathic Pain","Lidocaine",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT07086820","Window Prophylaxis for Pediatric Tuberculosis Prevention Trial","2028-05","Tuberculosis window prophylaxis with weekly rifapentine and isoniazid for 12 weeks",{"nctId":70,"briefTitle":71,"date":67,"intervention":72},"NCT07157657","Efficacy of a Photosynthetic Dermal Matrix for the Treatment of Full-Thickness Skin Wounds","Surgical implantation with standard (DRM) or photosynthetic dermal regeneration matrices (PDRM) in same patient.",[74,75,76,77,78,79],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[81,131,154,176,199,221,245,273,291,316,353,378,408,426,444,462,480,498,525,553,571,589,617,635,653,677,704,730,756,782,800,828,846,864,882,906,930,948,966,996,1014,1041,1059,1087,1114,1142,1167,1185,1209,1234,1260,1278,1303,1329,1356,1378,1410,1428,1455,1473,1498,1524,1549,1576,1594,1612,1637,1662,1687,1713,1740,1758,1776,1794,1819,1848,1866,1922,1968,1999,2025,2049,2077,2095,2113,2131,2156,2182,2200,2226,2254,2279,2304,2333,2351,2376,2401,2426,2444,2462,2487,2514,2532,2556,2582],{"intervention":63,"totalTrials":82,"cells":83},3,{"EARLY_PHASE1":84,"PHASE1":87,"PHASE2":89,"PHASE3":101,"PHASE4":103,"NA":129},{"trials":85,"activeCount":86},[],0,{"trials":88,"activeCount":86},[],{"trials":90,"activeCount":100,"soonestReadout":58},[91],{"nctId":61,"briefTitle":62,"status":92,"phases":93,"primaryCompletion":58,"completion":94,"start":95,"enrollment":96,"conditions":97,"interventions":99},"NOT_YET_RECRUITING",[75,76],"2026-12-23","2026-05-15",30,[98],"Neuropathic Chronic Pain",[63],1,{"trials":102,"activeCount":86},[],{"trials":104,"activeCount":86},[105,118],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":116},"NCT02121119","Lidocaine Versus Bupivacaine in Ambulatory Continuous Block With Elastomeric Pump","COMPLETED",[78],"2014-09","2015-09","2013-09",70,[115],"Hallux Valgus",[63,117],"Bupivacaine",{"nctId":119,"briefTitle":120,"status":108,"phases":121,"primaryCompletion":122,"completion":122,"start":123,"enrollment":124,"conditions":125,"interventions":127},"NCT01986309","Intravenous Lidocaine in the Prevention of Postoperative Vomiting in Elective Tonsil Surgery",[78],"2013-06","2012-03",92,[126,17],"Postoperative Nausea and Vomiting",[63,128],"Normal saline",{"trials":130,"activeCount":86},[],{"intervention":44,"totalTrials":100,"cells":132},{"EARLY_PHASE1":133,"PHASE1":135,"PHASE2":137,"PHASE3":148,"PHASE4":150,"NA":152},{"trials":134,"activeCount":86},[],{"trials":136,"activeCount":86},[],{"trials":138,"activeCount":100,"soonestReadout":43},[139],{"nctId":41,"briefTitle":42,"status":140,"phases":141,"primaryCompletion":43,"completion":142,"start":143,"enrollment":144,"conditions":145,"interventions":147},"RECRUITING",[76],"2026-06-30","2022-08-01",50,[146],"Acute Coronary Syndrome",[44],{"trials":149,"activeCount":86},[],{"trials":151,"activeCount":86},[],{"trials":153,"activeCount":86},[],{"intervention":72,"totalTrials":100,"cells":155},{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":160,"PHASE3":170,"PHASE4":172,"NA":174},{"trials":157,"activeCount":86},[],{"trials":159,"activeCount":86},[],{"trials":161,"activeCount":100,"soonestReadout":67},[162],{"nctId":70,"briefTitle":71,"status":140,"phases":163,"primaryCompletion":67,"completion":67,"start":164,"enrollment":165,"conditions":166,"interventions":169},[76],"2025-06-24",20,[167,168],"Cronic Full-thinkness Skin Wound","Acute Full-thickness Skin Wound",[72],{"trials":171,"activeCount":86},[],{"trials":173,"activeCount":86},[],{"trials":175,"activeCount":86},[],{"intervention":59,"totalTrials":100,"cells":177},{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":184,"PHASE4":186,"NA":188},{"trials":179,"activeCount":86},[],{"trials":181,"activeCount":86},[],{"trials":183,"activeCount":86},[],{"trials":185,"activeCount":86},[],{"trials":187,"activeCount":86},[],{"trials":189,"activeCount":100,"soonestReadout":58},[190],{"nctId":56,"briefTitle":57,"status":92,"phases":191,"primaryCompletion":58,"completion":192,"start":193,"enrollment":194,"conditions":195,"interventions":198},[79],"2027-12-01","2026-03-01",40,[17,196,197,117],"Interscalene Blocks","Dexamethasone",[59],{"intervention":49,"totalTrials":100,"cells":200},{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":209,"NA":211},{"trials":202,"activeCount":86},[],{"trials":204,"activeCount":86},[],{"trials":206,"activeCount":86},[],{"trials":208,"activeCount":86},[],{"trials":210,"activeCount":86},[],{"trials":212,"activeCount":100,"soonestReadout":48},[213],{"nctId":46,"briefTitle":47,"status":140,"phases":214,"primaryCompletion":48,"completion":215,"start":216,"enrollment":217,"conditions":218,"interventions":220},[],"2026-12-15","2025-02-14",80,[219],"Sedation Complication",[49],{"intervention":39,"totalTrials":100,"cells":222},{"EARLY_PHASE1":223,"PHASE1":225,"PHASE2":227,"PHASE3":229,"PHASE4":231,"NA":233},{"trials":224,"activeCount":86},[],{"trials":226,"activeCount":86},[],{"trials":228,"activeCount":86},[],{"trials":230,"activeCount":86},[],{"trials":232,"activeCount":86},[],{"trials":234,"activeCount":100,"soonestReadout":38},[235],{"nctId":36,"briefTitle":37,"status":140,"phases":236,"primaryCompletion":38,"completion":237,"start":238,"enrollment":239,"conditions":240,"interventions":244},[79],"2027-01","2025-01-24",72,[241,242,243],"Inflammatory Bowel Disease (IBD)","Crohn Disease (CD)","Ulcerative Colitis (UC)",[39,39],{"intervention":68,"totalTrials":100,"cells":246},{"EARLY_PHASE1":247,"PHASE1":249,"PHASE2":251,"PHASE3":253,"PHASE4":255,"NA":257},{"trials":248,"activeCount":86},[],{"trials":250,"activeCount":86},[],{"trials":252,"activeCount":86},[],{"trials":254,"activeCount":86},[],{"trials":256,"activeCount":86},[],{"trials":258,"activeCount":100,"soonestReadout":67},[259],{"nctId":65,"briefTitle":66,"status":140,"phases":260,"primaryCompletion":67,"completion":261,"start":262,"enrollment":263,"conditions":264,"interventions":271},[79],"2028-11","2025-10-27",647,[265,266,267,268,269,270],"Tuberculosis Infection","Household Contacts","Children","Adolescent","Tuberculosis Infection, Latent","Tuberculosis",[68,272],"Standard of care tuberculosis prophylaxis with weekly rifapentine and isoniazid for 12 weeks",{"intervention":272,"totalTrials":100,"cells":274},{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":279,"PHASE3":281,"PHASE4":283,"NA":285},{"trials":276,"activeCount":86},[],{"trials":278,"activeCount":86},[],{"trials":280,"activeCount":86},[],{"trials":282,"activeCount":86},[],{"trials":284,"activeCount":86},[],{"trials":286,"activeCount":100,"soonestReadout":67},[287],{"nctId":65,"briefTitle":66,"status":140,"phases":288,"primaryCompletion":67,"completion":261,"start":262,"enrollment":263,"conditions":289,"interventions":290},[79],[265,266,267,268,269,270],[68,272],{"intervention":54,"totalTrials":100,"cells":292},{"EARLY_PHASE1":293,"PHASE1":295,"PHASE2":297,"PHASE3":299,"PHASE4":301,"NA":303},{"trials":294,"activeCount":86},[],{"trials":296,"activeCount":86},[],{"trials":298,"activeCount":86},[],{"trials":300,"activeCount":86},[],{"trials":302,"activeCount":86},[],{"trials":304,"activeCount":100,"soonestReadout":53},[305],{"nctId":51,"briefTitle":52,"status":140,"phases":306,"primaryCompletion":53,"completion":307,"start":308,"enrollment":309,"conditions":310,"interventions":315},[],"2027-10-27","2026-01-29",150,[311,312,313,314],"Nociception","Artificial Intelligence (AI)","Target Controlled Infusion (TCI)","Remifentanil Consumption",[54],{"intervention":317,"totalTrials":318,"cells":319},"Ezetimibe",2,{"EARLY_PHASE1":320,"PHASE1":322,"PHASE2":335,"PHASE3":337,"PHASE4":339,"NA":351},{"trials":321,"activeCount":86},[],{"trials":323,"activeCount":86},[324],{"nctId":325,"briefTitle":326,"status":327,"phases":328,"primaryCompletion":329,"completion":330,"start":331,"enrollment":165,"conditions":332,"interventions":334},"NCT02126137","Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection","UNKNOWN",[75],"2016-01","2016-03","2013-10",[333],"Chronic Hepatitis C",[317],{"trials":336,"activeCount":86},[],{"trials":338,"activeCount":86},[],{"trials":340,"activeCount":86},[341],{"nctId":342,"briefTitle":343,"status":327,"phases":344,"primaryCompletion":345,"completion":346,"start":122,"enrollment":347,"conditions":348,"interventions":350},"NCT02768545","Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2)",[78],"2016-05","2016-06",12,[349],"Hepatitis C",[317],{"trials":352,"activeCount":86},[],{"intervention":354,"totalTrials":100,"cells":355},"H-Bupivacaine",{"EARLY_PHASE1":356,"PHASE1":358,"PHASE2":360,"PHASE3":362,"PHASE4":364,"NA":376},{"trials":357,"activeCount":86},[],{"trials":359,"activeCount":86},[],{"trials":361,"activeCount":86},[],{"trials":363,"activeCount":86},[],{"trials":365,"activeCount":86},[366],{"nctId":367,"briefTitle":368,"status":327,"phases":369,"primaryCompletion":370,"completion":329,"start":371,"enrollment":217,"conditions":372,"interventions":374},"NCT02387060","Use of Intrathecal Fentanyl and Development of Hyperalgesia in Patients Undergoing Elective Cesarean",[78],"2015-12","2014-08",[373],"Complications; Cesarean Section",[354,375],"Fentanyl",{"trials":377,"activeCount":86},[],{"intervention":379,"totalTrials":100,"cells":380},"Levobupivacaine 5 mL",{"EARLY_PHASE1":381,"PHASE1":383,"PHASE2":385,"PHASE3":387,"PHASE4":389,"NA":406},{"trials":382,"activeCount":86},[],{"trials":384,"activeCount":86},[],{"trials":386,"activeCount":86},[],{"trials":388,"activeCount":86},[],{"trials":390,"activeCount":86},[391],{"nctId":392,"briefTitle":393,"status":327,"phases":394,"primaryCompletion":395,"completion":396,"start":329,"enrollment":397,"conditions":398,"interventions":400},"NCT02557386","Optimal Volume of Bupivacaine in Adductor Canal Nerve Block",[78],"2016-12","2017-03",60,[399],"Anesthesia, Local",[379,401,402,403,404,405],"Levobupivacaine 10 mL","Levobupivacaine 15 mL","Levobupivacaine 20 mL","Levobupivacaine 25 mL","Levobupivacaine 30 mL",{"trials":407,"activeCount":86},[],{"intervention":401,"totalTrials":100,"cells":409},{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":416,"PHASE4":418,"NA":424},{"trials":411,"activeCount":86},[],{"trials":413,"activeCount":86},[],{"trials":415,"activeCount":86},[],{"trials":417,"activeCount":86},[],{"trials":419,"activeCount":86},[420],{"nctId":392,"briefTitle":393,"status":327,"phases":421,"primaryCompletion":395,"completion":396,"start":329,"enrollment":397,"conditions":422,"interventions":423},[78],[399],[379,401,402,403,404,405],{"trials":425,"activeCount":86},[],{"intervention":402,"totalTrials":100,"cells":427},{"EARLY_PHASE1":428,"PHASE1":430,"PHASE2":432,"PHASE3":434,"PHASE4":436,"NA":442},{"trials":429,"activeCount":86},[],{"trials":431,"activeCount":86},[],{"trials":433,"activeCount":86},[],{"trials":435,"activeCount":86},[],{"trials":437,"activeCount":86},[438],{"nctId":392,"briefTitle":393,"status":327,"phases":439,"primaryCompletion":395,"completion":396,"start":329,"enrollment":397,"conditions":440,"interventions":441},[78],[399],[379,401,402,403,404,405],{"trials":443,"activeCount":86},[],{"intervention":403,"totalTrials":100,"cells":445},{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":452,"PHASE4":454,"NA":460},{"trials":447,"activeCount":86},[],{"trials":449,"activeCount":86},[],{"trials":451,"activeCount":86},[],{"trials":453,"activeCount":86},[],{"trials":455,"activeCount":86},[456],{"nctId":392,"briefTitle":393,"status":327,"phases":457,"primaryCompletion":395,"completion":396,"start":329,"enrollment":397,"conditions":458,"interventions":459},[78],[399],[379,401,402,403,404,405],{"trials":461,"activeCount":86},[],{"intervention":404,"totalTrials":100,"cells":463},{"EARLY_PHASE1":464,"PHASE1":466,"PHASE2":468,"PHASE3":470,"PHASE4":472,"NA":478},{"trials":465,"activeCount":86},[],{"trials":467,"activeCount":86},[],{"trials":469,"activeCount":86},[],{"trials":471,"activeCount":86},[],{"trials":473,"activeCount":86},[474],{"nctId":392,"briefTitle":393,"status":327,"phases":475,"primaryCompletion":395,"completion":396,"start":329,"enrollment":397,"conditions":476,"interventions":477},[78],[399],[379,401,402,403,404,405],{"trials":479,"activeCount":86},[],{"intervention":405,"totalTrials":100,"cells":481},{"EARLY_PHASE1":482,"PHASE1":484,"PHASE2":486,"PHASE3":488,"PHASE4":490,"NA":496},{"trials":483,"activeCount":86},[],{"trials":485,"activeCount":86},[],{"trials":487,"activeCount":86},[],{"trials":489,"activeCount":86},[],{"trials":491,"activeCount":86},[492],{"nctId":392,"briefTitle":393,"status":327,"phases":493,"primaryCompletion":395,"completion":396,"start":329,"enrollment":397,"conditions":494,"interventions":495},[78],[399],[379,401,402,403,404,405],{"trials":497,"activeCount":86},[],{"intervention":499,"totalTrials":100,"cells":500},"Acetaminophen",{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":505,"PHASE3":507,"PHASE4":509,"NA":523},{"trials":502,"activeCount":86},[],{"trials":504,"activeCount":86},[],{"trials":506,"activeCount":86},[],{"trials":508,"activeCount":86},[],{"trials":510,"activeCount":86},[511],{"nctId":512,"briefTitle":513,"status":108,"phases":514,"primaryCompletion":515,"completion":516,"start":517,"enrollment":518,"conditions":519,"interventions":522},"NCT04779567","Usefulness of Acetaminophen Associated With Strong Opioids for Acute Pain in Cancer Patients",[78],"2021-06-11","2021-06-14","2019-06-10",112,[520,521],"Acute Pain","Cancer Pain",[499],{"trials":524,"activeCount":86},[],{"intervention":526,"totalTrials":100,"cells":527},"Codeine",{"EARLY_PHASE1":528,"PHASE1":530,"PHASE2":532,"PHASE3":534,"PHASE4":536,"NA":551},{"trials":529,"activeCount":86},[],{"trials":531,"activeCount":86},[],{"trials":533,"activeCount":86},[],{"trials":535,"activeCount":86},[],{"trials":537,"activeCount":86},[538],{"nctId":539,"briefTitle":540,"status":108,"phases":541,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":548},"NCT06907355","CHAO Tos: Codeina, HederA Helix, LevOdropropizina Para la TOS",[78],"2025-11-22","2025-12-01","2025-05-13",196,[547],"Upper Resp Tract Infection",[526,549,550],"Levodropropizine","Ivy Leaves Cough Liquid",{"trials":552,"activeCount":86},[],{"intervention":549,"totalTrials":100,"cells":554},{"EARLY_PHASE1":555,"PHASE1":557,"PHASE2":559,"PHASE3":561,"PHASE4":563,"NA":569},{"trials":556,"activeCount":86},[],{"trials":558,"activeCount":86},[],{"trials":560,"activeCount":86},[],{"trials":562,"activeCount":86},[],{"trials":564,"activeCount":86},[565],{"nctId":539,"briefTitle":540,"status":108,"phases":566,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":567,"interventions":568},[78],[547],[526,549,550],{"trials":570,"activeCount":86},[],{"intervention":550,"totalTrials":100,"cells":572},{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":579,"PHASE4":581,"NA":587},{"trials":574,"activeCount":86},[],{"trials":576,"activeCount":86},[],{"trials":578,"activeCount":86},[],{"trials":580,"activeCount":86},[],{"trials":582,"activeCount":86},[583],{"nctId":539,"briefTitle":540,"status":108,"phases":584,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":585,"interventions":586},[78],[547],[526,549,550],{"trials":588,"activeCount":86},[],{"intervention":590,"totalTrials":100,"cells":591},"0.9% Sodium-chloride",{"EARLY_PHASE1":592,"PHASE1":594,"PHASE2":596,"PHASE3":598,"PHASE4":600,"NA":615},{"trials":593,"activeCount":86},[],{"trials":595,"activeCount":86},[],{"trials":597,"activeCount":86},[],{"trials":599,"activeCount":86},[],{"trials":601,"activeCount":86},[602],{"nctId":603,"briefTitle":604,"status":108,"phases":605,"primaryCompletion":606,"completion":606,"start":607,"enrollment":194,"conditions":608,"interventions":612},"NCT03809182","Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels.",[78],"2013-07-25","2012-09-27",[609,610,611],"Bariatric Surgery Candidate","Glucose Intolerance","Insulin Resistance",[613,590,375,614],"Dexmedetomidine","Morphine Sulfate",{"trials":616,"activeCount":86},[],{"intervention":614,"totalTrials":100,"cells":618},{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":623,"PHASE3":625,"PHASE4":627,"NA":633},{"trials":620,"activeCount":86},[],{"trials":622,"activeCount":86},[],{"trials":624,"activeCount":86},[],{"trials":626,"activeCount":86},[],{"trials":628,"activeCount":86},[629],{"nctId":603,"briefTitle":604,"status":108,"phases":630,"primaryCompletion":606,"completion":606,"start":607,"enrollment":194,"conditions":631,"interventions":632},[78],[609,610,611],[613,590,375,614],{"trials":634,"activeCount":86},[],{"intervention":117,"totalTrials":100,"cells":636},{"EARLY_PHASE1":637,"PHASE1":639,"PHASE2":641,"PHASE3":643,"PHASE4":645,"NA":651},{"trials":638,"activeCount":86},[],{"trials":640,"activeCount":86},[],{"trials":642,"activeCount":86},[],{"trials":644,"activeCount":86},[],{"trials":646,"activeCount":86},[647],{"nctId":106,"briefTitle":107,"status":108,"phases":648,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":649,"interventions":650},[78],[115],[63,117],{"trials":652,"activeCount":86},[],{"intervention":654,"totalTrials":100,"cells":655},"Sodium Chloride 0.9%",{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":662,"PHASE4":664,"NA":675},{"trials":657,"activeCount":86},[],{"trials":659,"activeCount":86},[],{"trials":661,"activeCount":86},[],{"trials":663,"activeCount":86},[],{"trials":665,"activeCount":86},[666],{"nctId":667,"briefTitle":668,"status":327,"phases":669,"primaryCompletion":670,"completion":671,"start":111,"enrollment":194,"conditions":672,"interventions":674},"NCT02549768","Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery",[78],"2017-07","2017-08",[673],"Pituitary Neoplasms",[613,654],{"trials":676,"activeCount":86},[],{"intervention":678,"totalTrials":100,"cells":679},"Artificial Saliva",{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":686,"PHASE4":688,"NA":702},{"trials":681,"activeCount":86},[],{"trials":683,"activeCount":86},[],{"trials":685,"activeCount":86},[],{"trials":687,"activeCount":86},[],{"trials":689,"activeCount":86},[690],{"nctId":691,"briefTitle":692,"status":108,"phases":693,"primaryCompletion":694,"completion":694,"start":695,"enrollment":696,"conditions":697,"interventions":701},"NCT00438048","A Comparison of Orally Pilocarpine and Artificial Saliva in Xerostomy Treatment",[78],"2008-05","2006-11",76,[698,699,700],"Primary Sjogren","Secondary Sjogren","Xerostomia",[678],{"trials":703,"activeCount":86},[],{"intervention":705,"totalTrials":100,"cells":706},"Intravenous patient-controlled analgesia",{"EARLY_PHASE1":707,"PHASE1":709,"PHASE2":711,"PHASE3":713,"PHASE4":715,"NA":728},{"trials":708,"activeCount":86},[],{"trials":710,"activeCount":86},[],{"trials":712,"activeCount":86},[],{"trials":714,"activeCount":86},[],{"trials":716,"activeCount":86},[717],{"nctId":718,"briefTitle":719,"status":108,"phases":720,"primaryCompletion":721,"start":722,"enrollment":723,"conditions":724,"interventions":727},"NCT01961895","Lumbar Plexus Block Upon the Incidence of Ischemic Cardiovascular Events in Elderly Patients With Hip Fracture",[78],"2012-05","2010-05",31,[725,726],"Hip Fractures","Perioperative Myocardial Ischemia",[705],{"trials":729,"activeCount":86},[],{"intervention":731,"totalTrials":100,"cells":732},"Hepatitis B recombinant vaccine",{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":739,"PHASE4":741,"NA":754},{"trials":734,"activeCount":86},[],{"trials":736,"activeCount":86},[],{"trials":738,"activeCount":86},[],{"trials":740,"activeCount":86},[],{"trials":742,"activeCount":86},[743],{"nctId":744,"briefTitle":745,"status":327,"phases":746,"primaryCompletion":747,"completion":748,"start":749,"enrollment":750,"conditions":751,"interventions":753},"NCT04326803","Hepatitis B en Haitian Immigrants in Chile: Molecular Characterization and Determination of Vaccine Response",[78],"2022-06-30","2023-12-30","2020-06-01",200,[752],"Hepatitis B",[731],{"trials":755,"activeCount":86},[],{"intervention":757,"totalTrials":100,"cells":758},"Levobupivacaine with epinephrine",{"EARLY_PHASE1":759,"PHASE1":761,"PHASE2":763,"PHASE3":765,"PHASE4":767,"NA":780},{"trials":760,"activeCount":86},[],{"trials":762,"activeCount":86},[],{"trials":764,"activeCount":86},[],{"trials":766,"activeCount":86},[],{"trials":768,"activeCount":86},[769],{"nctId":770,"briefTitle":771,"status":108,"phases":772,"primaryCompletion":773,"completion":773,"start":774,"enrollment":775,"conditions":776,"interventions":778},"NCT01596998","Plasma Concentrations of Levobupivacaine With and Without Epinephrine in Transversus Abdominis Plane Blocks",[78],"2012-04","2011-12",11,[777],"Transversus Abdominis Plane Block",[757,779],"Levobupivacaine without epinephrine",{"trials":781,"activeCount":86},[],{"intervention":779,"totalTrials":100,"cells":783},{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":788,"PHASE3":790,"PHASE4":792,"NA":798},{"trials":785,"activeCount":86},[],{"trials":787,"activeCount":86},[],{"trials":789,"activeCount":86},[],{"trials":791,"activeCount":86},[],{"trials":793,"activeCount":86},[794],{"nctId":770,"briefTitle":771,"status":108,"phases":795,"primaryCompletion":773,"completion":773,"start":774,"enrollment":775,"conditions":796,"interventions":797},[78],[777],[757,779],{"trials":799,"activeCount":86},[],{"intervention":801,"totalTrials":100,"cells":802},"Water",{"EARLY_PHASE1":803,"PHASE1":805,"PHASE2":807,"PHASE3":809,"PHASE4":811,"NA":826},{"trials":804,"activeCount":86},[],{"trials":806,"activeCount":86},[],{"trials":808,"activeCount":86},[],{"trials":810,"activeCount":86},[],{"trials":812,"activeCount":86},[813],{"nctId":814,"briefTitle":815,"status":108,"phases":816,"primaryCompletion":331,"completion":817,"start":818,"enrollment":819,"conditions":820,"interventions":822},"NCT01653171","Premedication With Simethicone or Simethicone Plus N-acetylcysteine in Improving Visibility During Upper Endoscopy",[78],"2013-11","2012-07",230,[821],"Stomach Neoplasms",[801,823,824,825],"Simethicone","N-acetylcysteine 500 mg","N-acetylcysteine 1000 mg",{"trials":827,"activeCount":86},[],{"intervention":823,"totalTrials":100,"cells":829},{"EARLY_PHASE1":830,"PHASE1":832,"PHASE2":834,"PHASE3":836,"PHASE4":838,"NA":844},{"trials":831,"activeCount":86},[],{"trials":833,"activeCount":86},[],{"trials":835,"activeCount":86},[],{"trials":837,"activeCount":86},[],{"trials":839,"activeCount":86},[840],{"nctId":814,"briefTitle":815,"status":108,"phases":841,"primaryCompletion":331,"completion":817,"start":818,"enrollment":819,"conditions":842,"interventions":843},[78],[821],[801,823,824,825],{"trials":845,"activeCount":86},[],{"intervention":824,"totalTrials":100,"cells":847},{"EARLY_PHASE1":848,"PHASE1":850,"PHASE2":852,"PHASE3":854,"PHASE4":856,"NA":862},{"trials":849,"activeCount":86},[],{"trials":851,"activeCount":86},[],{"trials":853,"activeCount":86},[],{"trials":855,"activeCount":86},[],{"trials":857,"activeCount":86},[858],{"nctId":814,"briefTitle":815,"status":108,"phases":859,"primaryCompletion":331,"completion":817,"start":818,"enrollment":819,"conditions":860,"interventions":861},[78],[821],[801,823,824,825],{"trials":863,"activeCount":86},[],{"intervention":825,"totalTrials":100,"cells":865},{"EARLY_PHASE1":866,"PHASE1":868,"PHASE2":870,"PHASE3":872,"PHASE4":874,"NA":880},{"trials":867,"activeCount":86},[],{"trials":869,"activeCount":86},[],{"trials":871,"activeCount":86},[],{"trials":873,"activeCount":86},[],{"trials":875,"activeCount":86},[876],{"nctId":814,"briefTitle":815,"status":108,"phases":877,"primaryCompletion":331,"completion":817,"start":818,"enrollment":819,"conditions":878,"interventions":879},[78],[821],[801,823,824,825],{"trials":881,"activeCount":86},[],{"intervention":883,"totalTrials":100,"cells":884},"Surfactant",{"EARLY_PHASE1":885,"PHASE1":887,"PHASE2":889,"PHASE3":891,"PHASE4":893,"NA":904},{"trials":886,"activeCount":86},[],{"trials":888,"activeCount":86},[],{"trials":890,"activeCount":86},[],{"trials":892,"activeCount":86},[],{"trials":894,"activeCount":86},[895],{"nctId":896,"briefTitle":897,"status":327,"phases":898,"start":899,"enrollment":900,"conditions":901,"interventions":903},"NCT00277030","Two Strategies of RDS Treatment in Newborns With Birth Weight > 1500 Grams",[78],"2006-01",110,[902],"Respiratory Distress Syndrome",[883],{"trials":905,"activeCount":86},[],{"intervention":907,"totalTrials":100,"cells":908},"Cyclopentolate",{"EARLY_PHASE1":909,"PHASE1":911,"PHASE2":913,"PHASE3":915,"PHASE4":917,"NA":928},{"trials":910,"activeCount":86},[],{"trials":912,"activeCount":86},[],{"trials":914,"activeCount":86},[],{"trials":916,"activeCount":86},[],{"trials":918,"activeCount":86},[919],{"nctId":920,"briefTitle":921,"status":327,"phases":922,"primaryCompletion":371,"completion":110,"start":923,"enrollment":96,"conditions":924,"interventions":926},"NCT02177539","A New More Efficient Cycloplegia Scheme",[78],"2014-05",[925],"Refractive Errors",[907,927],"Cyclopentolate+tropicamide+phenylephrine",{"trials":929,"activeCount":86},[],{"intervention":927,"totalTrials":100,"cells":931},{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":936,"PHASE3":938,"PHASE4":940,"NA":946},{"trials":933,"activeCount":86},[],{"trials":935,"activeCount":86},[],{"trials":937,"activeCount":86},[],{"trials":939,"activeCount":86},[],{"trials":941,"activeCount":86},[942],{"nctId":920,"briefTitle":921,"status":327,"phases":943,"primaryCompletion":371,"completion":110,"start":923,"enrollment":96,"conditions":944,"interventions":945},[78],[925],[907,927],{"trials":947,"activeCount":86},[],{"intervention":128,"totalTrials":100,"cells":949},{"EARLY_PHASE1":950,"PHASE1":952,"PHASE2":954,"PHASE3":956,"PHASE4":958,"NA":964},{"trials":951,"activeCount":86},[],{"trials":953,"activeCount":86},[],{"trials":955,"activeCount":86},[],{"trials":957,"activeCount":86},[],{"trials":959,"activeCount":86},[960],{"nctId":119,"briefTitle":120,"status":108,"phases":961,"primaryCompletion":122,"completion":122,"start":123,"enrollment":124,"conditions":962,"interventions":963},[78],[126,17],[63,128],{"trials":965,"activeCount":86},[],{"intervention":967,"totalTrials":100,"cells":968},"Levobupivacaine 0.25% with epinephrine 5 ug\u002Fml",{"EARLY_PHASE1":969,"PHASE1":971,"PHASE2":973,"PHASE3":975,"PHASE4":977,"NA":994},{"trials":970,"activeCount":86},[],{"trials":972,"activeCount":86},[],{"trials":974,"activeCount":86},[],{"trials":976,"activeCount":86},[],{"trials":978,"activeCount":86},[979],{"nctId":980,"briefTitle":981,"status":108,"phases":982,"primaryCompletion":983,"completion":984,"start":985,"enrollment":986,"conditions":987,"interventions":992},"NCT04799184","PK\u002FPD Levobupivacaine with and Without Epinephrine After Ultrasound Guided ESP Block",[78],"2021-08-01","2022-03-09","2019-04-03",38,[988,989,990,991,32],"Anesthetics Complications","Anesthetic Toxicity","Bupivacaine Overdose","Nerve Block",[967,993],"Levobupivacaine 0.25% without epinephrine 5 ug\u002Fml",{"trials":995,"activeCount":86},[],{"intervention":993,"totalTrials":100,"cells":997},{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1002,"PHASE3":1004,"PHASE4":1006,"NA":1012},{"trials":999,"activeCount":86},[],{"trials":1001,"activeCount":86},[],{"trials":1003,"activeCount":86},[],{"trials":1005,"activeCount":86},[],{"trials":1007,"activeCount":86},[1008],{"nctId":980,"briefTitle":981,"status":108,"phases":1009,"primaryCompletion":983,"completion":984,"start":985,"enrollment":986,"conditions":1010,"interventions":1011},[78],[988,989,990,991,32],[967,993],{"trials":1013,"activeCount":86},[],{"intervention":1015,"totalTrials":100,"cells":1016},"Optimized bismuth quadruple therapy",{"EARLY_PHASE1":1017,"PHASE1":1019,"PHASE2":1021,"PHASE3":1023,"PHASE4":1025,"NA":1039},{"trials":1018,"activeCount":86},[],{"trials":1020,"activeCount":86},[],{"trials":1022,"activeCount":86},[],{"trials":1024,"activeCount":86},[],{"trials":1026,"activeCount":86},[1027],{"nctId":1028,"briefTitle":1029,"status":108,"phases":1030,"primaryCompletion":1031,"completion":1032,"start":1033,"enrollment":1034,"conditions":1035,"interventions":1037},"NCT05664685","Optimized Bismuth Quadruple Therapy vs Triple Standard Therapy for Helicobacter Pylori Eradication",[78],"2023-10-30","2024-01-30","2022-10-17",127,[1036],"Helicobacter Pylori Infection",[1015,1038],"Control",{"trials":1040,"activeCount":86},[],{"intervention":1038,"totalTrials":100,"cells":1042},{"EARLY_PHASE1":1043,"PHASE1":1045,"PHASE2":1047,"PHASE3":1049,"PHASE4":1051,"NA":1057},{"trials":1044,"activeCount":86},[],{"trials":1046,"activeCount":86},[],{"trials":1048,"activeCount":86},[],{"trials":1050,"activeCount":86},[],{"trials":1052,"activeCount":86},[1053],{"nctId":1028,"briefTitle":1029,"status":108,"phases":1054,"primaryCompletion":1031,"completion":1032,"start":1033,"enrollment":1034,"conditions":1055,"interventions":1056},[78],[1036],[1015,1038],{"trials":1058,"activeCount":86},[],{"intervention":1060,"totalTrials":100,"cells":1061},"Tamsulosin Hydrochloride 0.4 milligrams",{"EARLY_PHASE1":1062,"PHASE1":1064,"PHASE2":1066,"PHASE3":1068,"PHASE4":1070,"NA":1085},{"trials":1063,"activeCount":86},[],{"trials":1065,"activeCount":86},[],{"trials":1067,"activeCount":86},[],{"trials":1069,"activeCount":86},[],{"trials":1071,"activeCount":86},[1072],{"nctId":1073,"briefTitle":1074,"status":1075,"phases":1076,"primaryCompletion":1077,"completion":1077,"start":1078,"enrollment":1079,"conditions":1080,"interventions":1084},"NCT03614052","Tamsulosin as Adjuvant Treatment Prior to Endoscopic Ureterolithotomy","TERMINATED",[78],"2020-01-26","2018-06-01",14,[1081,1082,1083],"Ureterolithiasis","Ureteral Calculi","Urolithiasis",[1060],{"trials":1086,"activeCount":86},[],{"intervention":1088,"totalTrials":100,"cells":1089},"desmopressin",{"EARLY_PHASE1":1090,"PHASE1":1092,"PHASE2":1094,"PHASE3":1096,"PHASE4":1098,"NA":1112},{"trials":1091,"activeCount":86},[],{"trials":1093,"activeCount":86},[],{"trials":1095,"activeCount":86},[],{"trials":1097,"activeCount":86},[],{"trials":1099,"activeCount":86},[1100],{"nctId":1101,"briefTitle":1102,"status":108,"phases":1103,"primaryCompletion":1104,"completion":1105,"start":1106,"enrollment":15,"conditions":1107,"interventions":1111},"NCT01994330","Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery",[78],"2009-12","2010-02","2009-06",[1108,1109,1110],"Acquired Von Willebrand Disease Secondary to Severe Aortic Stenosis","Heye´s Syndrome","Severe Aortic Stenosis",[1088],{"trials":1113,"activeCount":86},[],{"intervention":1115,"totalTrials":100,"cells":1116},"Norepinephrine",{"EARLY_PHASE1":1117,"PHASE1":1119,"PHASE2":1121,"PHASE3":1123,"PHASE4":1125,"NA":1140},{"trials":1118,"activeCount":86},[],{"trials":1120,"activeCount":86},[],{"trials":1122,"activeCount":86},[],{"trials":1124,"activeCount":86},[],{"trials":1126,"activeCount":86},[1127],{"nctId":1128,"briefTitle":1129,"status":108,"phases":1130,"primaryCompletion":1131,"completion":1132,"start":1133,"enrollment":397,"conditions":1134,"interventions":1139},"NCT06574555","Norepinephrine ED90 Bolus After Spinal Anesthesia in Cesarean Section",[78],"2025-08-01","2025-08-02","2025-04-01",[1135,1136,1137,17,1138],"Hypotension","Hypertension","Nausea","Arrhythmia",[1115],{"trials":1141,"activeCount":86},[],{"intervention":1143,"totalTrials":100,"cells":1144},"Intravenous lidocaine",{"EARLY_PHASE1":1145,"PHASE1":1147,"PHASE2":1149,"PHASE3":1151,"PHASE4":1153,"NA":1165},{"trials":1146,"activeCount":86},[],{"trials":1148,"activeCount":86},[],{"trials":1150,"activeCount":86},[],{"trials":1152,"activeCount":86},[],{"trials":1154,"activeCount":86},[1155],{"nctId":1156,"briefTitle":1157,"status":108,"phases":1158,"primaryCompletion":1159,"completion":1159,"start":1160,"enrollment":194,"conditions":1161,"interventions":1163},"NCT01366300","Effect of Intravenous Lidocaine on BIS-guided Propofol Requirements During General Anesthesia",[78],"2011-06","2010-06",[1162],"Intravenous Anesthetic Interaction \"Unrecognized Condition\"",[1143,1164],"Propofol 1%",{"trials":1166,"activeCount":86},[],{"intervention":1164,"totalTrials":100,"cells":1168},{"EARLY_PHASE1":1169,"PHASE1":1171,"PHASE2":1173,"PHASE3":1175,"PHASE4":1177,"NA":1183},{"trials":1170,"activeCount":86},[],{"trials":1172,"activeCount":86},[],{"trials":1174,"activeCount":86},[],{"trials":1176,"activeCount":86},[],{"trials":1178,"activeCount":86},[1179],{"nctId":1156,"briefTitle":1157,"status":108,"phases":1180,"primaryCompletion":1159,"completion":1159,"start":1160,"enrollment":194,"conditions":1181,"interventions":1182},[78],[1162],[1143,1164],{"trials":1184,"activeCount":86},[],{"intervention":1186,"totalTrials":100,"cells":1187},"Levobupivacaine",{"EARLY_PHASE1":1188,"PHASE1":1190,"PHASE2":1192,"PHASE3":1194,"PHASE4":1196,"NA":1207},{"trials":1189,"activeCount":86},[],{"trials":1191,"activeCount":86},[],{"trials":1193,"activeCount":86},[],{"trials":1195,"activeCount":86},[],{"trials":1197,"activeCount":86},[1198],{"nctId":1199,"briefTitle":1200,"status":108,"phases":1201,"primaryCompletion":1202,"completion":1202,"start":1203,"enrollment":347,"conditions":1204,"interventions":1206},"NCT02852720","Pharmacokinetics of Levobupivacaine After Cesarean Section",[78],"2017-02-15","2016-12-15",[1205],"Pain, Postoperative",[1186],{"trials":1208,"activeCount":86},[],{"intervention":1210,"totalTrials":100,"cells":1211},"Methadone Injectable Product",{"EARLY_PHASE1":1212,"PHASE1":1214,"PHASE2":1216,"PHASE3":1218,"PHASE4":1220,"NA":1232},{"trials":1213,"activeCount":86},[],{"trials":1215,"activeCount":86},[],{"trials":1217,"activeCount":86},[],{"trials":1219,"activeCount":86},[],{"trials":1221,"activeCount":86},[1222],{"nctId":1223,"briefTitle":1224,"status":108,"phases":1225,"primaryCompletion":1226,"completion":1226,"start":1227,"enrollment":397,"conditions":1228,"interventions":1231},"NCT04526236","Influence of Aging on Perioperative Methadone Dosing",[78],"2022-07-13","2019-09-03",[1205,1229,1230],"Opioid Use","Methadone Overdose of Undetermined Intent",[1210],{"trials":1233,"activeCount":86},[],{"intervention":1235,"totalTrials":100,"cells":1236},"Propranolol",{"EARLY_PHASE1":1237,"PHASE1":1239,"PHASE2":1241,"PHASE3":1243,"PHASE4":1245,"NA":1258},{"trials":1238,"activeCount":86},[],{"trials":1240,"activeCount":86},[],{"trials":1242,"activeCount":86},[],{"trials":1244,"activeCount":86},[],{"trials":1246,"activeCount":86},[1247],{"nctId":1248,"briefTitle":1249,"status":327,"phases":1250,"primaryCompletion":1251,"completion":1252,"start":1253,"enrollment":217,"conditions":1254,"interventions":1256},"NCT02934763","Opioid Induced Hyperalgesia (OIH) Modulation With Propranolol",[78],"2017-04","2017-05","2016-10",[1255],"Hyperalgesia",[1235,1257],"Saline",{"trials":1259,"activeCount":86},[],{"intervention":1257,"totalTrials":100,"cells":1261},{"EARLY_PHASE1":1262,"PHASE1":1264,"PHASE2":1266,"PHASE3":1268,"PHASE4":1270,"NA":1276},{"trials":1263,"activeCount":86},[],{"trials":1265,"activeCount":86},[],{"trials":1267,"activeCount":86},[],{"trials":1269,"activeCount":86},[],{"trials":1271,"activeCount":86},[1272],{"nctId":1248,"briefTitle":1249,"status":327,"phases":1273,"primaryCompletion":1251,"completion":1252,"start":1253,"enrollment":217,"conditions":1274,"interventions":1275},[78],[1255],[1235,1257],{"trials":1277,"activeCount":86},[],{"intervention":1279,"totalTrials":100,"cells":1280},"SARS-CoV-2 inactivated vaccine",{"EARLY_PHASE1":1281,"PHASE1":1283,"PHASE2":1285,"PHASE3":1287,"PHASE4":1299,"NA":1301},{"trials":1282,"activeCount":86},[],{"trials":1284,"activeCount":86},[],{"trials":1286,"activeCount":86},[],{"trials":1288,"activeCount":86},[1289],{"nctId":1290,"briefTitle":1291,"status":108,"phases":1292,"primaryCompletion":143,"completion":1293,"start":1294,"enrollment":1295,"conditions":1296,"interventions":1298},"NCT04651790","Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults",[77],"2022-11-01","2020-11-27",2300,[20,1297],"Vaccines",[1279],{"trials":1300,"activeCount":86},[],{"trials":1302,"activeCount":86},[],{"intervention":1304,"totalTrials":100,"cells":1305},"Tetravalent influenza vaccine developed by Sinovac Biotech Co.",{"EARLY_PHASE1":1306,"PHASE1":1308,"PHASE2":1310,"PHASE3":1312,"PHASE4":1325,"NA":1327},{"trials":1307,"activeCount":86},[],{"trials":1309,"activeCount":86},[],{"trials":1311,"activeCount":86},[],{"trials":1313,"activeCount":86},[1314],{"nctId":1315,"briefTitle":1316,"status":327,"phases":1317,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1321,"conditions":1322,"interventions":1324},"NCT05494047","Phase Ⅲ, Clinical Trial to Compare an Inactivated Quadrivalent Influenza Vaccine and a Licensed Vaccine in Chile",[77],"2023-05-31","2023-07-31","2022-07-14",1600,[1323,1297],"Influenza",[1304],{"trials":1326,"activeCount":86},[],{"trials":1328,"activeCount":86},[],{"intervention":1330,"totalTrials":100,"cells":1331},"Peginterferon beta-1a",{"EARLY_PHASE1":1332,"PHASE1":1334,"PHASE2":1336,"PHASE3":1338,"PHASE4":1352,"NA":1354},{"trials":1333,"activeCount":86},[],{"trials":1335,"activeCount":86},[],{"trials":1337,"activeCount":86},[],{"trials":1339,"activeCount":86},[1340],{"nctId":1341,"briefTitle":1342,"status":108,"phases":1343,"primaryCompletion":1344,"completion":1345,"start":1346,"enrollment":1347,"conditions":1348,"interventions":1351},"NCT04552379","The Containing Coronavirus Disease 19 (COVID-19) Trial",[77],"2021-05-31","2021-06-30","2020-12-01",1173,[1349,1350,20],"SARS-CoV Infection","Interferon",[1330],{"trials":1353,"activeCount":86},[],{"trials":1355,"activeCount":86},[],{"intervention":1357,"totalTrials":100,"cells":1358},"Topical 2,5% lidocaine + 2,5% prilocaine gel",{"EARLY_PHASE1":1359,"PHASE1":1361,"PHASE2":1363,"PHASE3":1365,"PHASE4":1374,"NA":1376},{"trials":1360,"activeCount":86},[],{"trials":1362,"activeCount":86},[],{"trials":1364,"activeCount":86},[],{"trials":1366,"activeCount":86},[1367],{"nctId":1368,"briefTitle":1369,"status":108,"phases":1370,"primaryCompletion":345,"completion":345,"start":923,"enrollment":217,"conditions":1371,"interventions":1373},"NCT02130830","Topical Anesthesia Versus Placebo to Decrease Pain in Rubber Band Ligation for Treatment of Internal Hemorrhoids",[77],[1372,17],"Hemorrhoids",[1357],{"trials":1375,"activeCount":86},[],{"trials":1377,"activeCount":86},[],{"intervention":1379,"totalTrials":100,"cells":1380},"Autologous Serum 20%",{"EARLY_PHASE1":1381,"PHASE1":1383,"PHASE2":1385,"PHASE3":1387,"PHASE4":1406,"NA":1408},{"trials":1382,"activeCount":86},[],{"trials":1384,"activeCount":86},[],{"trials":1386,"activeCount":86},[],{"trials":1388,"activeCount":86},[1389],{"nctId":1390,"briefTitle":1391,"status":327,"phases":1392,"primaryCompletion":1393,"completion":1394,"start":1395,"enrollment":165,"conditions":1396,"interventions":1404},"NCT03436576","Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye",[77],"2018-10-19","2018-11-19","2018-09-12",[1397,1398,1399,1400,1401,1402,1403],"Dry Eye","Keratoconjunctivitis Sicca","Sjogren's Syndrome","Corneal Diseases","Conjunctival Diseases","Keratitis","Lacrimal Apparatus Diseases",[1379,1405],"Autologous Serum 50%",{"trials":1407,"activeCount":86},[],{"trials":1409,"activeCount":86},[],{"intervention":1405,"totalTrials":100,"cells":1411},{"EARLY_PHASE1":1412,"PHASE1":1414,"PHASE2":1416,"PHASE3":1418,"PHASE4":1424,"NA":1426},{"trials":1413,"activeCount":86},[],{"trials":1415,"activeCount":86},[],{"trials":1417,"activeCount":86},[],{"trials":1419,"activeCount":86},[1420],{"nctId":1390,"briefTitle":1391,"status":327,"phases":1421,"primaryCompletion":1393,"completion":1394,"start":1395,"enrollment":165,"conditions":1422,"interventions":1423},[77],[1397,1398,1399,1400,1401,1402,1403],[1379,1405],{"trials":1425,"activeCount":86},[],{"trials":1427,"activeCount":86},[],{"intervention":1429,"totalTrials":100,"cells":1430},"Triple combination cream",{"EARLY_PHASE1":1431,"PHASE1":1433,"PHASE2":1435,"PHASE3":1449,"PHASE4":1451,"NA":1453},{"trials":1432,"activeCount":86},[],{"trials":1434,"activeCount":86},[],{"trials":1436,"activeCount":86},[1437],{"nctId":1438,"briefTitle":1439,"status":108,"phases":1440,"primaryCompletion":1441,"completion":1442,"start":1443,"enrollment":1444,"conditions":1445,"interventions":1447},"NCT00975312","Solar Lentigines Treatment With the Triple Combination Cream",[76],"2008-11","2009-02","2008-08",22,[1446],"Lentigo",[1429,1448],"Tretinoin 0.05%",{"trials":1450,"activeCount":86},[],{"trials":1452,"activeCount":86},[],{"trials":1454,"activeCount":86},[],{"intervention":1448,"totalTrials":100,"cells":1456},{"EARLY_PHASE1":1457,"PHASE1":1459,"PHASE2":1461,"PHASE3":1467,"PHASE4":1469,"NA":1471},{"trials":1458,"activeCount":86},[],{"trials":1460,"activeCount":86},[],{"trials":1462,"activeCount":86},[1463],{"nctId":1438,"briefTitle":1439,"status":108,"phases":1464,"primaryCompletion":1441,"completion":1442,"start":1443,"enrollment":1444,"conditions":1465,"interventions":1466},[76],[1446],[1429,1448],{"trials":1468,"activeCount":86},[],{"trials":1470,"activeCount":86},[],{"trials":1472,"activeCount":86},[],{"intervention":1474,"totalTrials":100,"cells":1475},"Trimetazidine",{"EARLY_PHASE1":1476,"PHASE1":1478,"PHASE2":1480,"PHASE3":1492,"PHASE4":1494,"NA":1496},{"trials":1477,"activeCount":86},[],{"trials":1479,"activeCount":86},[],{"trials":1481,"activeCount":86},[1482],{"nctId":1483,"briefTitle":1484,"status":327,"phases":1485,"primaryCompletion":395,"completion":1486,"start":1487,"enrollment":1488,"conditions":1489,"interventions":1491},"NCT02102672","Trimetazidine in Pulmonary Artery Hypertension",[76],"2017-12","2014-03",25,[1490],"Pulmonary Artery Hypertension",[1474],{"trials":1493,"activeCount":86},[],{"trials":1495,"activeCount":86},[],{"trials":1497,"activeCount":86},[],{"intervention":1499,"totalTrials":100,"cells":1500},"Interferon-Alpha2B",{"EARLY_PHASE1":1501,"PHASE1":1503,"PHASE2":1505,"PHASE3":1518,"PHASE4":1520,"NA":1522},{"trials":1502,"activeCount":86},[],{"trials":1504,"activeCount":86},[],{"trials":1506,"activeCount":86},[1507],{"nctId":1508,"briefTitle":1509,"status":108,"phases":1510,"primaryCompletion":1511,"completion":1512,"start":1513,"enrollment":1514,"conditions":1515,"interventions":1517},"NCT04988217","Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)",[75,76],"2022-04-15","2022-07-28","2021-09-15",173,[1516],"Coronavirus Disease 2019",[1499],{"trials":1519,"activeCount":86},[],{"trials":1521,"activeCount":86},[],{"trials":1523,"activeCount":86},[],{"intervention":1525,"totalTrials":100,"cells":1526},"pravastatin",{"EARLY_PHASE1":1527,"PHASE1":1529,"PHASE2":1531,"PHASE3":1543,"PHASE4":1545,"NA":1547},{"trials":1528,"activeCount":86},[],{"trials":1530,"activeCount":86},[],{"trials":1532,"activeCount":86},[1533],{"nctId":1534,"briefTitle":1535,"status":1536,"phases":1537,"completion":1538,"start":1539,"enrollment":86,"conditions":1540,"interventions":1542},"NCT00305201","Cardiovascular Risk Markers and Response to Statins After Kawasaki Disease","WITHDRAWN",[76],"2007-05","2006-04",[1541],"Kawasaki Disease",[1525],{"trials":1544,"activeCount":86},[],{"trials":1546,"activeCount":86},[],{"trials":1548,"activeCount":86},[],{"intervention":1550,"totalTrials":100,"cells":1551},"CoronaVac®",{"EARLY_PHASE1":1552,"PHASE1":1554,"PHASE2":1556,"PHASE3":1570,"PHASE4":1572,"NA":1574},{"trials":1553,"activeCount":86},[],{"trials":1555,"activeCount":86},[],{"trials":1557,"activeCount":86},[1558],{"nctId":1559,"briefTitle":1560,"status":108,"phases":1561,"primaryCompletion":1562,"completion":1562,"start":1563,"enrollment":1564,"conditions":1565,"interventions":1567},"NCT05593042","Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile",[76],"2023-10-26","2022-11-28",551,[1566,1297],"COVID-19",[1550,1568,1569],"Omicron Vaccine","Trivalent Vaccine",{"trials":1571,"activeCount":86},[],{"trials":1573,"activeCount":86},[],{"trials":1575,"activeCount":86},[],{"intervention":1568,"totalTrials":100,"cells":1577},{"EARLY_PHASE1":1578,"PHASE1":1580,"PHASE2":1582,"PHASE3":1588,"PHASE4":1590,"NA":1592},{"trials":1579,"activeCount":86},[],{"trials":1581,"activeCount":86},[],{"trials":1583,"activeCount":86},[1584],{"nctId":1559,"briefTitle":1560,"status":108,"phases":1585,"primaryCompletion":1562,"completion":1562,"start":1563,"enrollment":1564,"conditions":1586,"interventions":1587},[76],[1566,1297],[1550,1568,1569],{"trials":1589,"activeCount":86},[],{"trials":1591,"activeCount":86},[],{"trials":1593,"activeCount":86},[],{"intervention":1569,"totalTrials":100,"cells":1595},{"EARLY_PHASE1":1596,"PHASE1":1598,"PHASE2":1600,"PHASE3":1606,"PHASE4":1608,"NA":1610},{"trials":1597,"activeCount":86},[],{"trials":1599,"activeCount":86},[],{"trials":1601,"activeCount":86},[1602],{"nctId":1559,"briefTitle":1560,"status":108,"phases":1603,"primaryCompletion":1562,"completion":1562,"start":1563,"enrollment":1564,"conditions":1604,"interventions":1605},[76],[1566,1297],[1550,1568,1569],{"trials":1607,"activeCount":86},[],{"trials":1609,"activeCount":86},[],{"trials":1611,"activeCount":86},[],{"intervention":1613,"totalTrials":100,"cells":1614},"Conventional therapy",{"EARLY_PHASE1":1615,"PHASE1":1617,"PHASE2":1619,"PHASE3":1631,"PHASE4":1633,"NA":1635},{"trials":1616,"activeCount":86},[],{"trials":1618,"activeCount":86},[],{"trials":1620,"activeCount":86},[1621],{"nctId":1622,"briefTitle":1623,"status":108,"phases":1624,"primaryCompletion":1625,"completion":1625,"start":1626,"enrollment":1627,"conditions":1628,"interventions":1630},"NCT01245946","Photodynamic Therapy Compared to Adapalene 0.1% Gel Plus Doxycycline in the Treatment of Acne Vulgaris",[76],"2011-05","2010-10",46,[1629],"Acne",[1613],{"trials":1632,"activeCount":86},[],{"trials":1634,"activeCount":86},[],{"trials":1636,"activeCount":86},[],{"intervention":1638,"totalTrials":100,"cells":1639},"Topical 25% sodium metabisulfite (SM) in pediatric cold cream",{"EARLY_PHASE1":1640,"PHASE1":1642,"PHASE2":1644,"PHASE3":1656,"PHASE4":1658,"NA":1660},{"trials":1641,"activeCount":86},[],{"trials":1643,"activeCount":86},[],{"trials":1645,"activeCount":86},[1646],{"nctId":1647,"briefTitle":1648,"status":327,"phases":1649,"primaryCompletion":1650,"completion":1650,"start":1651,"enrollment":165,"conditions":1652,"interventions":1655},"NCT06155578","Safety and Efficacy of Topical Sodium Metabisulfite for the Treatment of Calcinosis in Patients With Systemic Sclerosis",[75,76],"2024-12-31","2024-01-02",[1653,1654],"Systemic Sclerosis","Calcinosis",[1638],{"trials":1657,"activeCount":86},[],{"trials":1659,"activeCount":86},[],{"trials":1661,"activeCount":86},[],{"intervention":1663,"totalTrials":100,"cells":1664},"COVID-19 convalescent plasma",{"EARLY_PHASE1":1665,"PHASE1":1667,"PHASE2":1669,"PHASE3":1681,"PHASE4":1683,"NA":1685},{"trials":1666,"activeCount":86},[],{"trials":1668,"activeCount":86},[],{"trials":1670,"activeCount":86},[1671],{"nctId":1672,"briefTitle":1673,"status":108,"phases":1674,"primaryCompletion":1675,"completion":1675,"start":1676,"enrollment":1677,"conditions":1678,"interventions":1680},"NCT04375098","Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection",[76],"2020-08-17","2020-05-04",58,[1679],"Severe Acute Respiratory Syndrome Coronavirus 2",[1663],{"trials":1682,"activeCount":86},[],{"trials":1684,"activeCount":86},[],{"trials":1686,"activeCount":86},[],{"intervention":1688,"totalTrials":100,"cells":1689},"3 protocols of Indomethacin administration",{"EARLY_PHASE1":1690,"PHASE1":1692,"PHASE2":1694,"PHASE3":1707,"PHASE4":1709,"NA":1711},{"trials":1691,"activeCount":86},[],{"trials":1693,"activeCount":86},[],{"trials":1695,"activeCount":86},[1696],{"nctId":1697,"briefTitle":1698,"status":327,"phases":1699,"primaryCompletion":1700,"completion":1104,"start":1443,"enrollment":1701,"conditions":1702,"interventions":1706},"NCT00722033","Common Neonatal Procedures Could Affect the aEEG in \u003C30 Weeks of Gestational Age Preterms",[76],"2009-08",10,[1703,1704,1705],"Regional Blood Flow","Premature Birth","Electroencephalography",[1688],{"trials":1708,"activeCount":86},[],{"trials":1710,"activeCount":86},[],{"trials":1712,"activeCount":86},[],{"intervention":1714,"totalTrials":100,"cells":1715},"rBCG-N-hRSV 1\u002F100",{"EARLY_PHASE1":1716,"PHASE1":1718,"PHASE2":1732,"PHASE3":1734,"PHASE4":1736,"NA":1738},{"trials":1717,"activeCount":86},[],{"trials":1719,"activeCount":86},[1720],{"nctId":1721,"briefTitle":1722,"status":108,"phases":1723,"primaryCompletion":1078,"completion":1078,"start":1724,"enrollment":1725,"conditions":1726,"interventions":1728},"NCT03213405","A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuated hRSV Vaccine rBCG-N-hRSV",[75],"2017-06-27",24,[1727],"Respiratory Syncytial Virus Infections",[1714,1729,1730,1731],"rBCG-N-hRSV 1\u002F10","rBCG-N-hRSV full dose","Conventional BCG full dose",{"trials":1733,"activeCount":86},[],{"trials":1735,"activeCount":86},[],{"trials":1737,"activeCount":86},[],{"trials":1739,"activeCount":86},[],{"intervention":1729,"totalTrials":100,"cells":1741},{"EARLY_PHASE1":1742,"PHASE1":1744,"PHASE2":1750,"PHASE3":1752,"PHASE4":1754,"NA":1756},{"trials":1743,"activeCount":86},[],{"trials":1745,"activeCount":86},[1746],{"nctId":1721,"briefTitle":1722,"status":108,"phases":1747,"primaryCompletion":1078,"completion":1078,"start":1724,"enrollment":1725,"conditions":1748,"interventions":1749},[75],[1727],[1714,1729,1730,1731],{"trials":1751,"activeCount":86},[],{"trials":1753,"activeCount":86},[],{"trials":1755,"activeCount":86},[],{"trials":1757,"activeCount":86},[],{"intervention":1730,"totalTrials":100,"cells":1759},{"EARLY_PHASE1":1760,"PHASE1":1762,"PHASE2":1768,"PHASE3":1770,"PHASE4":1772,"NA":1774},{"trials":1761,"activeCount":86},[],{"trials":1763,"activeCount":86},[1764],{"nctId":1721,"briefTitle":1722,"status":108,"phases":1765,"primaryCompletion":1078,"completion":1078,"start":1724,"enrollment":1725,"conditions":1766,"interventions":1767},[75],[1727],[1714,1729,1730,1731],{"trials":1769,"activeCount":86},[],{"trials":1771,"activeCount":86},[],{"trials":1773,"activeCount":86},[],{"trials":1775,"activeCount":86},[],{"intervention":1731,"totalTrials":100,"cells":1777},{"EARLY_PHASE1":1778,"PHASE1":1780,"PHASE2":1786,"PHASE3":1788,"PHASE4":1790,"NA":1792},{"trials":1779,"activeCount":86},[],{"trials":1781,"activeCount":86},[1782],{"nctId":1721,"briefTitle":1722,"status":108,"phases":1783,"primaryCompletion":1078,"completion":1078,"start":1724,"enrollment":1725,"conditions":1784,"interventions":1785},[75],[1727],[1714,1729,1730,1731],{"trials":1787,"activeCount":86},[],{"trials":1789,"activeCount":86},[],{"trials":1791,"activeCount":86},[],{"trials":1793,"activeCount":86},[],{"intervention":1795,"totalTrials":100,"cells":1796},"Dermal regeneration photosynthetic matrix",{"EARLY_PHASE1":1797,"PHASE1":1809,"PHASE2":1811,"PHASE3":1813,"PHASE4":1815,"NA":1817},{"trials":1798,"activeCount":86},[1799],{"nctId":1800,"briefTitle":1801,"status":108,"phases":1802,"primaryCompletion":1803,"completion":1804,"start":1805,"enrollment":165,"conditions":1806,"interventions":1808},"NCT03960164","Dermal Regeneration Photosynthetic Matrix",[74],"2023-06-30","2023-11-01","2019-04-01",[1807],"Skin Wound",[1795],{"trials":1810,"activeCount":86},[],{"trials":1812,"activeCount":86},[],{"trials":1814,"activeCount":86},[],{"trials":1816,"activeCount":86},[],{"trials":1818,"activeCount":86},[],{"intervention":1820,"totalTrials":100,"cells":1821},"10% nifedipine cream",{"EARLY_PHASE1":1822,"PHASE1":1838,"PHASE2":1840,"PHASE3":1842,"PHASE4":1844,"NA":1846},{"trials":1823,"activeCount":86},[1824],{"nctId":1825,"briefTitle":1826,"status":108,"phases":1827,"primaryCompletion":1828,"completion":1828,"start":1828,"enrollment":1701,"conditions":1829,"interventions":1836},"NCT03027674","Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud",[74],"2016-08",[1830,1831,1832,1833,1834,1835],"Raynaud Phenomenon Due to Trauma","Raynaud Disease","System; Sclerosis","Lupus Erythematosus, Systemic","Dermatomyositis","Ultrasound Therapy; Complications",[1820,1837],"5% sildenafil cream",{"trials":1839,"activeCount":86},[],{"trials":1841,"activeCount":86},[],{"trials":1843,"activeCount":86},[],{"trials":1845,"activeCount":86},[],{"trials":1847,"activeCount":86},[],{"intervention":1837,"totalTrials":100,"cells":1849},{"EARLY_PHASE1":1850,"PHASE1":1856,"PHASE2":1858,"PHASE3":1860,"PHASE4":1862,"NA":1864},{"trials":1851,"activeCount":86},[1852],{"nctId":1825,"briefTitle":1826,"status":108,"phases":1853,"primaryCompletion":1828,"completion":1828,"start":1828,"enrollment":1701,"conditions":1854,"interventions":1855},[74],[1830,1831,1832,1833,1834,1835],[1820,1837],{"trials":1857,"activeCount":86},[],{"trials":1859,"activeCount":86},[],{"trials":1861,"activeCount":86},[],{"trials":1863,"activeCount":86},[],{"trials":1865,"activeCount":86},[],{"intervention":1867,"totalTrials":30,"cells":1868},"Propofol",{"EARLY_PHASE1":1869,"PHASE1":1871,"PHASE2":1873,"PHASE3":1875,"PHASE4":1877,"NA":1891},{"trials":1870,"activeCount":86},[],{"trials":1872,"activeCount":86},[],{"trials":1874,"activeCount":86},[],{"trials":1876,"activeCount":86},[],{"trials":1878,"activeCount":86},[1879,1885],{"nctId":1880,"briefTitle":1881,"status":327,"phases":1882,"primaryCompletion":395,"completion":395,"start":111,"enrollment":194,"conditions":1883,"interventions":1884},"NCT02544854","Pharmacokinetic\u002FPharmacodynamic Model of Propofol in Children",[78],[14],[1867],{"nctId":1886,"briefTitle":1887,"status":108,"phases":1888,"primaryCompletion":773,"completion":721,"start":123,"enrollment":165,"conditions":1889,"interventions":1890},"NCT01596387","Validation of a Pharmacokinetic Pharmacodynamic Model to Administer Propofol in Obese Patients",[78],[27],[1867],{"trials":1892,"activeCount":86},[1893,1904,1913],{"nctId":1894,"briefTitle":1895,"status":108,"phases":1896,"primaryCompletion":1897,"completion":1898,"start":1899,"enrollment":96,"conditions":1900,"interventions":1903},"NCT04774120","Relationship Between Bispectral Index, EEG Features, and Propofol Effect-site Concentration in Young and Elderly Patients.",[],"2021-03-30","2021-05-30","2020-12-11",[1705,1901,1867,1902],"Aging","Depth of Anesthesia",[1867],{"nctId":1905,"briefTitle":1906,"status":1075,"phases":1907,"primaryCompletion":1908,"completion":1909,"start":1910,"enrollment":347,"conditions":1911,"interventions":1912},"NCT03195530","Bispectral Index (BIS) Values Required for an Adequate Depth of Anesthesia in Elderly Patients Using Propofol",[],"2018-01-31","2018-03-31","2017-05-01",[14],[1867],{"nctId":1914,"briefTitle":1915,"status":327,"phases":1916,"primaryCompletion":1917,"completion":1131,"start":1918,"enrollment":397,"conditions":1919,"interventions":1921},"NCT05790720","Development of a Pharmacodynamic Model for Propofol in Older Adults",[79],"2025-07-01","2024-06-01",[1920],"Aged",[1867],{"intervention":613,"totalTrials":30,"cells":1923},{"EARLY_PHASE1":1924,"PHASE1":1926,"PHASE2":1928,"PHASE3":1930,"PHASE4":1932,"NA":1956},{"trials":1925,"activeCount":86},[],{"trials":1927,"activeCount":86},[],{"trials":1929,"activeCount":86},[],{"trials":1931,"activeCount":86},[],{"trials":1933,"activeCount":86},[1934,1938,1942,1949],{"nctId":603,"briefTitle":604,"status":108,"phases":1935,"primaryCompletion":606,"completion":606,"start":607,"enrollment":194,"conditions":1936,"interventions":1937},[78],[609,610,611],[613,590,375,614],{"nctId":667,"briefTitle":668,"status":327,"phases":1939,"primaryCompletion":670,"completion":671,"start":111,"enrollment":194,"conditions":1940,"interventions":1941},[78],[673],[613,654],{"nctId":1943,"briefTitle":1944,"status":327,"phases":1945,"primaryCompletion":1253,"completion":1486,"start":1946,"enrollment":194,"conditions":1947,"interventions":1948},"NCT02557867","The Effect of Obesity in Dexmedetomidine Metabolic Clearance",[78],"2015-08",[27],[613],{"nctId":1950,"briefTitle":1951,"status":108,"phases":1952,"primaryCompletion":1953,"completion":923,"start":773,"enrollment":194,"conditions":1954,"interventions":1955},"NCT02187068","Dexmedetomidine Pharmacokinetics in the Obese",[78],"2012-12",[27],[613],{"trials":1957,"activeCount":86},[1958],{"nctId":1959,"briefTitle":1960,"status":108,"phases":1961,"primaryCompletion":1962,"completion":1963,"start":1964,"enrollment":1965,"conditions":1966,"interventions":1967},"NCT04973124","The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients",[79],"2024-08-30","2024-11-01","2021-11-16",43,[14,613,1901],[613],{"intervention":375,"totalTrials":82,"cells":1969},{"EARLY_PHASE1":1970,"PHASE1":1972,"PHASE2":1974,"PHASE3":1976,"PHASE4":1978,"NA":1988},{"trials":1971,"activeCount":86},[],{"trials":1973,"activeCount":86},[],{"trials":1975,"activeCount":86},[],{"trials":1977,"activeCount":86},[],{"trials":1979,"activeCount":86},[1980,1984],{"nctId":367,"briefTitle":368,"status":327,"phases":1981,"primaryCompletion":370,"completion":329,"start":371,"enrollment":217,"conditions":1982,"interventions":1983},[78],[373],[354,375],{"nctId":603,"briefTitle":604,"status":108,"phases":1985,"primaryCompletion":606,"completion":606,"start":607,"enrollment":194,"conditions":1986,"interventions":1987},[78],[609,610,611],[613,590,375,614],{"trials":1989,"activeCount":86},[1990],{"nctId":1991,"briefTitle":1992,"status":108,"phases":1993,"primaryCompletion":1994,"completion":1995,"start":1346,"enrollment":1488,"conditions":1996,"interventions":1998},"NCT04786275","Evaluation of the Nociception Guided by NoL Index and PK of Fentanyl in Pediatric Patients Under General Anesthesia",[],"2022-12-31","2023-03-31",[17,14,1997],"Pediatric ALL",[375],{"intervention":2000,"totalTrials":100,"cells":2001},"Amikacin Sulfate",{"EARLY_PHASE1":2002,"PHASE1":2004,"PHASE2":2006,"PHASE3":2008,"PHASE4":2010,"NA":2012},{"trials":2003,"activeCount":86},[],{"trials":2005,"activeCount":86},[],{"trials":2007,"activeCount":86},[],{"trials":2009,"activeCount":86},[],{"trials":2011,"activeCount":86},[],{"trials":2013,"activeCount":86},[2014],{"nctId":2015,"briefTitle":2016,"status":108,"phases":2017,"primaryCompletion":2018,"completion":2019,"start":2020,"enrollment":2021,"conditions":2022,"interventions":2024},"NCT04867135","Population Pharmacokinetics of Amikacin in Neonates",[],"2021-07-31","2021-09-03","2019-12-01",138,[2023],"Neonatal Sepsis, Late-Onset",[2000],{"intervention":2026,"totalTrials":100,"cells":2027},"Tacrolimus",{"EARLY_PHASE1":2028,"PHASE1":2030,"PHASE2":2032,"PHASE3":2034,"PHASE4":2036,"NA":2038},{"trials":2029,"activeCount":86},[],{"trials":2031,"activeCount":86},[],{"trials":2033,"activeCount":86},[],{"trials":2035,"activeCount":86},[],{"trials":2037,"activeCount":86},[],{"trials":2039,"activeCount":86},[2040],{"nctId":2041,"briefTitle":2042,"status":108,"phases":2043,"primaryCompletion":330,"completion":330,"start":2044,"enrollment":165,"conditions":2045,"interventions":2048},"NCT02608606","Determining Equivalence Dose for Oral Versus Sublingual Administration of Tacrolimus in Hepatic Receptors",[79],"2015-03",[2046,2047],"Evidence of Liver Transplantation","Effects of Immunosuppressant Therapy",[2026],{"intervention":2050,"totalTrials":100,"cells":2051},"Propofol Group 1",{"EARLY_PHASE1":2052,"PHASE1":2054,"PHASE2":2056,"PHASE3":2058,"PHASE4":2060,"NA":2062},{"trials":2053,"activeCount":86},[],{"trials":2055,"activeCount":86},[],{"trials":2057,"activeCount":86},[],{"trials":2059,"activeCount":86},[],{"trials":2061,"activeCount":86},[],{"trials":2063,"activeCount":86},[2064],{"nctId":2065,"briefTitle":2066,"status":108,"phases":2067,"primaryCompletion":2068,"completion":2069,"start":2070,"enrollment":165,"conditions":2071,"interventions":2073},"NCT04904965","Frontal Electroencephalography of Neonatal Patients Under Sedation With Opioids and General Anesthesia With Propofol.",[79],"2022-12-03","2023-03-03","2021-05-03",[14,32,2072,1902],"Neonate",[2050,2074,2075,2076],"Propofol Group 2","Propofol Group 3","Propofol Group 4",{"intervention":2074,"totalTrials":100,"cells":2078},{"EARLY_PHASE1":2079,"PHASE1":2081,"PHASE2":2083,"PHASE3":2085,"PHASE4":2087,"NA":2089},{"trials":2080,"activeCount":86},[],{"trials":2082,"activeCount":86},[],{"trials":2084,"activeCount":86},[],{"trials":2086,"activeCount":86},[],{"trials":2088,"activeCount":86},[],{"trials":2090,"activeCount":86},[2091],{"nctId":2065,"briefTitle":2066,"status":108,"phases":2092,"primaryCompletion":2068,"completion":2069,"start":2070,"enrollment":165,"conditions":2093,"interventions":2094},[79],[14,32,2072,1902],[2050,2074,2075,2076],{"intervention":2075,"totalTrials":100,"cells":2096},{"EARLY_PHASE1":2097,"PHASE1":2099,"PHASE2":2101,"PHASE3":2103,"PHASE4":2105,"NA":2107},{"trials":2098,"activeCount":86},[],{"trials":2100,"activeCount":86},[],{"trials":2102,"activeCount":86},[],{"trials":2104,"activeCount":86},[],{"trials":2106,"activeCount":86},[],{"trials":2108,"activeCount":86},[2109],{"nctId":2065,"briefTitle":2066,"status":108,"phases":2110,"primaryCompletion":2068,"completion":2069,"start":2070,"enrollment":165,"conditions":2111,"interventions":2112},[79],[14,32,2072,1902],[2050,2074,2075,2076],{"intervention":2076,"totalTrials":100,"cells":2114},{"EARLY_PHASE1":2115,"PHASE1":2117,"PHASE2":2119,"PHASE3":2121,"PHASE4":2123,"NA":2125},{"trials":2116,"activeCount":86},[],{"trials":2118,"activeCount":86},[],{"trials":2120,"activeCount":86},[],{"trials":2122,"activeCount":86},[],{"trials":2124,"activeCount":86},[],{"trials":2126,"activeCount":86},[2127],{"nctId":2065,"briefTitle":2066,"status":108,"phases":2128,"primaryCompletion":2068,"completion":2069,"start":2070,"enrollment":165,"conditions":2129,"interventions":2130},[79],[14,32,2072,1902],[2050,2074,2075,2076],{"intervention":2132,"totalTrials":100,"cells":2133},"Respiratory bundle",{"EARLY_PHASE1":2134,"PHASE1":2136,"PHASE2":2138,"PHASE3":2140,"PHASE4":2142,"NA":2144},{"trials":2135,"activeCount":86},[],{"trials":2137,"activeCount":86},[],{"trials":2139,"activeCount":86},[],{"trials":2141,"activeCount":86},[],{"trials":2143,"activeCount":86},[],{"trials":2145,"activeCount":86},[2146],{"nctId":2147,"briefTitle":2148,"status":108,"phases":2149,"primaryCompletion":2150,"completion":2150,"start":2151,"enrollment":2152,"conditions":2153,"interventions":2155},"NCT04938596","Airborne Preventive Measures to Reduce New TB Infections in Household Contacts",[79],"2024-03-30","2021-10-04",432,[2154,266,270],"Tuberculosis, Pulmonary",[2132],{"intervention":2157,"totalTrials":100,"cells":2158},"Intraoperative",{"EARLY_PHASE1":2159,"PHASE1":2161,"PHASE2":2163,"PHASE3":2165,"PHASE4":2167,"NA":2169},{"trials":2160,"activeCount":86},[],{"trials":2162,"activeCount":86},[],{"trials":2164,"activeCount":86},[],{"trials":2166,"activeCount":86},[],{"trials":2168,"activeCount":86},[],{"trials":2170,"activeCount":86},[2171],{"nctId":2172,"briefTitle":2173,"status":327,"phases":2174,"primaryCompletion":1650,"completion":1650,"start":2175,"enrollment":165,"conditions":2176,"interventions":2180},"NCT06056245","Methadone Pharmacokinetics in End-stage Renal Disease",[],"2024-04-05",[2177,2178,2179],"Chronic Kidney Diseases","Post Operative Pain","Pain, Acute",[2157,2181],"Post-operative",{"intervention":2181,"totalTrials":100,"cells":2183},{"EARLY_PHASE1":2184,"PHASE1":2186,"PHASE2":2188,"PHASE3":2190,"PHASE4":2192,"NA":2194},{"trials":2185,"activeCount":86},[],{"trials":2187,"activeCount":86},[],{"trials":2189,"activeCount":86},[],{"trials":2191,"activeCount":86},[],{"trials":2193,"activeCount":86},[],{"trials":2195,"activeCount":86},[2196],{"nctId":2172,"briefTitle":2173,"status":327,"phases":2197,"primaryCompletion":1650,"completion":1650,"start":2175,"enrollment":165,"conditions":2198,"interventions":2199},[],[2177,2178,2179],[2157,2181],{"intervention":2201,"totalTrials":100,"cells":2202},"Methadone",{"EARLY_PHASE1":2203,"PHASE1":2205,"PHASE2":2207,"PHASE3":2209,"PHASE4":2211,"NA":2213},{"trials":2204,"activeCount":86},[],{"trials":2206,"activeCount":86},[],{"trials":2208,"activeCount":86},[],{"trials":2210,"activeCount":86},[],{"trials":2212,"activeCount":86},[],{"trials":2214,"activeCount":86},[2215],{"nctId":2216,"briefTitle":2217,"status":108,"phases":2218,"primaryCompletion":1994,"completion":2219,"start":2220,"enrollment":2221,"conditions":2222,"interventions":2225},"NCT05075265","Methadone in Adults Undergoing Cardiac Surgery",[],"2023-06-01","2021-10-02",29,[2223,2224,2201],"Cardiosurgery","Cardiopulmonary Bypass",[2201],{"intervention":2227,"totalTrials":100,"cells":2228},"Lidocaine topical",{"EARLY_PHASE1":2229,"PHASE1":2231,"PHASE2":2233,"PHASE3":2235,"PHASE4":2237,"NA":2239},{"trials":2230,"activeCount":86},[],{"trials":2232,"activeCount":86},[],{"trials":2234,"activeCount":86},[],{"trials":2236,"activeCount":86},[],{"trials":2238,"activeCount":86},[],{"trials":2240,"activeCount":86},[2241],{"nctId":2242,"briefTitle":2243,"status":108,"phases":2244,"primaryCompletion":2245,"completion":2246,"start":2247,"enrollment":165,"conditions":2248,"interventions":2253},"NCT06171243","PK of Lidocaine\u002FTetracaine and PD Derived From a New Topical Formulation for Treatment of Neuropathic Pain.",[],"2024-09-23","2025-07-28","2023-03-17",[2249,2250,2251,2252],"Neuralgia","Neuropathic Pain","Local Anesthetic Complication","Lidocaine Adverse Reaction",[2227],{"intervention":2255,"totalTrials":100,"cells":2256},"Ketamine",{"EARLY_PHASE1":2257,"PHASE1":2259,"PHASE2":2261,"PHASE3":2263,"PHASE4":2265,"NA":2267},{"trials":2258,"activeCount":86},[],{"trials":2260,"activeCount":86},[],{"trials":2262,"activeCount":86},[],{"trials":2264,"activeCount":86},[],{"trials":2266,"activeCount":86},[],{"trials":2268,"activeCount":86},[2269],{"nctId":2270,"briefTitle":2271,"status":108,"phases":2272,"primaryCompletion":2273,"completion":2273,"start":2274,"enrollment":165,"conditions":2275,"interventions":2278},"NCT06344858","Characterization of the Temporal Profile of the Anti-nociceptive Effect of Ketamine Bolus Measured With ANI",[],"2024-08-01","2024-04-30",[2276,2255,2277],"Analgesia","Pharmacokinetic",[2255],{"intervention":2280,"totalTrials":100,"cells":2281},"Exposure: COVID-19 severity",{"EARLY_PHASE1":2282,"PHASE1":2284,"PHASE2":2286,"PHASE3":2288,"PHASE4":2290,"NA":2292},{"trials":2283,"activeCount":86},[],{"trials":2285,"activeCount":86},[],{"trials":2287,"activeCount":86},[],{"trials":2289,"activeCount":86},[],{"trials":2291,"activeCount":86},[],{"trials":2293,"activeCount":86},[2294],{"nctId":2295,"briefTitle":2296,"status":327,"phases":2297,"primaryCompletion":2298,"completion":2299,"start":2300,"enrollment":217,"conditions":2301,"interventions":2303},"NCT05019300","Long-term Neurocognitive and Psychiatric Consequences in Severe COVID-19 Survivors.",[],"2021-09","2021-10","2021-05-24",[20,2302],"Neurocognitive Dysfunction",[2280],{"intervention":2305,"totalTrials":100,"cells":2306},"Three doses of SARS-CoV-2 BNT162b2 vaccine",{"EARLY_PHASE1":2307,"PHASE1":2309,"PHASE2":2311,"PHASE3":2313,"PHASE4":2315,"NA":2317},{"trials":2308,"activeCount":86},[],{"trials":2310,"activeCount":86},[],{"trials":2312,"activeCount":86},[],{"trials":2314,"activeCount":86},[],{"trials":2316,"activeCount":86},[],{"trials":2318,"activeCount":86},[2319],{"nctId":2320,"briefTitle":2321,"status":108,"phases":2322,"primaryCompletion":2323,"completion":2324,"start":2325,"enrollment":2326,"conditions":2327,"interventions":2331},"NCT05124509","Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant",[],"2021-12-13","2022-01-03","2021-10-06",147,[1566,2328,2329,2330],"SARS-CoV-2 Infection","Solid Organ Transplant","Vaccine Response Impaired",[2305,2332],"Two doses of CoronaVac and one dose of BNT162b2 SARS-CoV-2 vaccine",{"intervention":2332,"totalTrials":100,"cells":2334},{"EARLY_PHASE1":2335,"PHASE1":2337,"PHASE2":2339,"PHASE3":2341,"PHASE4":2343,"NA":2345},{"trials":2336,"activeCount":86},[],{"trials":2338,"activeCount":86},[],{"trials":2340,"activeCount":86},[],{"trials":2342,"activeCount":86},[],{"trials":2344,"activeCount":86},[],{"trials":2346,"activeCount":86},[2347],{"nctId":2320,"briefTitle":2321,"status":108,"phases":2348,"primaryCompletion":2323,"completion":2324,"start":2325,"enrollment":2326,"conditions":2349,"interventions":2350},[],[1566,2328,2329,2330],[2305,2332],{"intervention":2352,"totalTrials":100,"cells":2353},"conversion from CNI to MMF",{"EARLY_PHASE1":2354,"PHASE1":2356,"PHASE2":2358,"PHASE3":2360,"PHASE4":2362,"NA":2364},{"trials":2355,"activeCount":86},[],{"trials":2357,"activeCount":86},[],{"trials":2359,"activeCount":86},[],{"trials":2361,"activeCount":86},[],{"trials":2363,"activeCount":86},[],{"trials":2365,"activeCount":86},[2366],{"nctId":2367,"briefTitle":2368,"status":327,"phases":2369,"primaryCompletion":1487,"completion":1487,"start":2370,"enrollment":194,"conditions":2371,"interventions":2375},"NCT01321112","Search for Transcriptional Biomarkers in a Conversion Protocol From Calcineurin Inhibitors to Mycophenolate Mofetil",[79],"2011-02",[2372,2373,2374],"Gene Expression","Immunosuppression Conversion","Liver Transplantation",[2352],{"intervention":2377,"totalTrials":100,"cells":2378},"blood withdraw",{"EARLY_PHASE1":2379,"PHASE1":2381,"PHASE2":2383,"PHASE3":2385,"PHASE4":2387,"NA":2389},{"trials":2380,"activeCount":86},[],{"trials":2382,"activeCount":86},[],{"trials":2384,"activeCount":86},[],{"trials":2386,"activeCount":86},[],{"trials":2388,"activeCount":86},[],{"trials":2390,"activeCount":86},[2391],{"nctId":2392,"briefTitle":2393,"status":327,"phases":2394,"primaryCompletion":2395,"completion":2395,"start":2396,"enrollment":2397,"conditions":2398,"interventions":2400},"NCT04142723","Alcoholic Hepatitis in Latin-America: A Prospective and Multicentric Study (AH-LATIN).",[],"2022-06-20","2019-06-20",1000,[2399],"Hepatitis, Alcoholic",[2377],{"intervention":2402,"totalTrials":100,"cells":2403},"Best medical treatment",{"EARLY_PHASE1":2404,"PHASE1":2406,"PHASE2":2408,"PHASE3":2410,"PHASE4":2412,"NA":2414},{"trials":2405,"activeCount":86},[],{"trials":2407,"activeCount":86},[],{"trials":2409,"activeCount":86},[],{"trials":2411,"activeCount":86},[],{"trials":2413,"activeCount":86},[],{"trials":2415,"activeCount":86},[2416],{"nctId":2417,"briefTitle":2418,"status":327,"phases":2419,"primaryCompletion":370,"completion":395,"start":2420,"enrollment":309,"conditions":2421,"interventions":2423},"NCT01974544","Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines",[79],"2013-05",[2422],"Type 2 Diabetes",[2402,2424,2425],"General interventions for all groups: blood presure","General interventions for all groups: dysilipidemia",{"intervention":2424,"totalTrials":100,"cells":2427},{"EARLY_PHASE1":2428,"PHASE1":2430,"PHASE2":2432,"PHASE3":2434,"PHASE4":2436,"NA":2438},{"trials":2429,"activeCount":86},[],{"trials":2431,"activeCount":86},[],{"trials":2433,"activeCount":86},[],{"trials":2435,"activeCount":86},[],{"trials":2437,"activeCount":86},[],{"trials":2439,"activeCount":86},[2440],{"nctId":2417,"briefTitle":2418,"status":327,"phases":2441,"primaryCompletion":370,"completion":395,"start":2420,"enrollment":309,"conditions":2442,"interventions":2443},[79],[2422],[2402,2424,2425],{"intervention":2425,"totalTrials":100,"cells":2445},{"EARLY_PHASE1":2446,"PHASE1":2448,"PHASE2":2450,"PHASE3":2452,"PHASE4":2454,"NA":2456},{"trials":2447,"activeCount":86},[],{"trials":2449,"activeCount":86},[],{"trials":2451,"activeCount":86},[],{"trials":2453,"activeCount":86},[],{"trials":2455,"activeCount":86},[],{"trials":2457,"activeCount":86},[2458],{"nctId":2417,"briefTitle":2418,"status":327,"phases":2459,"primaryCompletion":370,"completion":395,"start":2420,"enrollment":309,"conditions":2460,"interventions":2461},[79],[2422],[2402,2424,2425],{"intervention":2463,"totalTrials":100,"cells":2464},"Vasopressor test",{"EARLY_PHASE1":2465,"PHASE1":2467,"PHASE2":2469,"PHASE3":2471,"PHASE4":2473,"NA":2475},{"trials":2466,"activeCount":86},[],{"trials":2468,"activeCount":86},[],{"trials":2470,"activeCount":86},[],{"trials":2472,"activeCount":86},[],{"trials":2474,"activeCount":86},[],{"trials":2476,"activeCount":86},[2477],{"nctId":2478,"briefTitle":2479,"status":327,"phases":2480,"primaryCompletion":2481,"completion":2482,"start":1293,"enrollment":144,"conditions":2483,"interventions":2486},"NCT06125184","Effect of Vasopressin on Kidney and Cardiac Function in Septic Shock",[79],"2024-10-01","2025-01-01",[2484,2485],"Kidney Injury, Acute","Cardiac Function Failed",[2463],{"intervention":2488,"totalTrials":100,"cells":2489},"Three doses of BNT162b2",{"EARLY_PHASE1":2490,"PHASE1":2492,"PHASE2":2494,"PHASE3":2496,"PHASE4":2498,"NA":2500},{"trials":2491,"activeCount":86},[],{"trials":2493,"activeCount":86},[],{"trials":2495,"activeCount":86},[],{"trials":2497,"activeCount":86},[],{"trials":2499,"activeCount":86},[],{"trials":2501,"activeCount":86},[2502],{"nctId":2503,"briefTitle":2504,"status":327,"phases":2505,"primaryCompletion":2506,"completion":2507,"start":2508,"enrollment":2509,"conditions":2510,"interventions":2512},"NCT05119738","Immune Response to Third Dose of SARS-CoV-2 Vaccine in a Cohort of Cancer Patients on Active Treatment",[],"2022-03-01","2022-06-01","2021-10-27",122,[2511],"Sars-CoV-2 Infection",[2488,2513],"Two doses of Coronavac and one dose BNT162b2",{"intervention":2513,"totalTrials":100,"cells":2515},{"EARLY_PHASE1":2516,"PHASE1":2518,"PHASE2":2520,"PHASE3":2522,"PHASE4":2524,"NA":2526},{"trials":2517,"activeCount":86},[],{"trials":2519,"activeCount":86},[],{"trials":2521,"activeCount":86},[],{"trials":2523,"activeCount":86},[],{"trials":2525,"activeCount":86},[],{"trials":2527,"activeCount":86},[2528],{"nctId":2503,"briefTitle":2504,"status":327,"phases":2529,"primaryCompletion":2506,"completion":2507,"start":2508,"enrollment":2509,"conditions":2530,"interventions":2531},[],[2511],[2488,2513],{"intervention":2533,"totalTrials":100,"cells":2534},"Rocuronium Bromide",{"EARLY_PHASE1":2535,"PHASE1":2537,"PHASE2":2539,"PHASE3":2541,"PHASE4":2543,"NA":2545},{"trials":2536,"activeCount":86},[],{"trials":2538,"activeCount":86},[],{"trials":2540,"activeCount":86},[],{"trials":2542,"activeCount":86},[],{"trials":2544,"activeCount":86},[],{"trials":2546,"activeCount":86},[2547],{"nctId":2548,"briefTitle":2549,"status":108,"phases":2550,"primaryCompletion":817,"completion":2551,"start":2552,"enrollment":1701,"conditions":2553,"interventions":2555},"NCT02376595","Pharmacokinetic and Pharmacodynamic of Rocuronium",[],"2015-01","2013-03",[2554],"Neuromuscular Blockade",[2533],{"intervention":2557,"totalTrials":100,"cells":2558},"Standardized Propofol Administration",{"EARLY_PHASE1":2559,"PHASE1":2561,"PHASE2":2563,"PHASE3":2565,"PHASE4":2567,"NA":2569},{"trials":2560,"activeCount":86},[],{"trials":2562,"activeCount":86},[],{"trials":2564,"activeCount":86},[],{"trials":2566,"activeCount":86},[],{"trials":2568,"activeCount":86},[],{"trials":2570,"activeCount":86},[2571],{"nctId":2572,"briefTitle":2573,"status":108,"phases":2574,"primaryCompletion":2575,"completion":2576,"start":2577,"enrollment":2578,"conditions":2579,"interventions":2581},"NCT04713644","Association Between Burst Suppression During Anesthetic Induction With Postoperative Delirium in Cardiac Surgery",[],"2024-02-28","2024-09-01","2021-03-01",78,[2580],"Postoperative Delirium",[2557],{"intervention":2583,"totalTrials":100,"cells":2584},"Dobutamine",{"EARLY_PHASE1":2585,"PHASE1":2587,"PHASE2":2589,"PHASE3":2591,"PHASE4":2593,"NA":2595},{"trials":2586,"activeCount":86},[],{"trials":2588,"activeCount":86},[],{"trials":2590,"activeCount":86},[],{"trials":2592,"activeCount":86},[],{"trials":2594,"activeCount":86},[],{"trials":2596,"activeCount":86},[2597],{"nctId":2598,"briefTitle":2599,"status":108,"phases":2600,"primaryCompletion":2601,"completion":2601,"start":2602,"enrollment":165,"conditions":2603,"interventions":2604},"NCT01271153","Effects of Dobutamine on Microcirculation, Regional and Peripheral Perfusion in Septic Shock Patients",[79],"2013-01","2010-08",[25],[2583]]